This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Dutta D, Huels J, Litschig S.Lumiracoxib is cost-effective and improves health-related quality of life in patients with osteoarthritis. 2007 Annual European Congress of Rheumatology: abstr. THU0435, 13 Jun 2007
Doan QV, Dubois RW, Omar M, Huels J.A financial impact assessment of introducing lumiracoxib onto the formulary of the UK National Health Service for the management of patients with osteoarthritis. 2007 Annual European Congress of Rheumatology: abstr. THU0433, 13 Jun 2007
Doan QV, Dubois RW, Omar M, Huels J.Comparison of the cost-effectiveness of lumiracoxib in patients with and without a history of gastrointestinal ulcer or bleed for the management of osteoarthritis. 2007 Annual European Congress of Rheumatology: abstr. THU0434, 13 Jun 2007
Rights and permissions
About this article
Cite this article
Lumiracoxib news from EULAR. Pharmacoecon. Outcomes News 533, 4 (2007). https://doi.org/10.1007/BF03296121
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03296121